In this regard, potential therapeutic agents appear to be elotuzumab, targeting SLAMF7, which is expressed in myeloma cells and nonmalignant plasma cells, as well as activated DN2 cells and circulating antibody-secreting cells (ASCs), in human SLE [185]. The gene discussed is SLAMF7; the disease is systemic lupus erythematosus.